ClinicalTrials.gg
Active, not recruitingNCT05910528TAHOEUpdated Sep 16, 2026

Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease

A Phase 2 interventional study of Afimkibart in Crohns Disease, sponsored by Hoffmann-La Roche. Active, not recruiting at 11 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Crohn Disease by Hoffmann-La Roche — 3 open to participants now, 4 under way, 3 of them phase 3. Crohn Disease · Hoffmann-La Roche.

Enrollment
9th of 10
21 · median 122
Started
2023
with 1 other
Phase 2
3 of 10
none open now
Registered
7th of 10
by date

Among the 10 studies in Crohn Disease by Hoffmann-La Roche, this one is the 9th largest by enrollment, is one of 2 that started in 2023, is one of 3 in phase 2, and was the 7th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

3 of the 10 studies in Crohn Disease by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Crohn Disease by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This Phase 2, randomized, double-blind, multicenter, induction and maintenance study is designed to evaluate the safety and efficacy of Afimkibart (RO7790121, RVT-3101) in adult participants with moderate to severe active Crohn's disease.

03

Conditions studied

  • Crohns Disease

Browse trials for

Keywords

  • Crohns Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Moderately to severely active CD as defined by CDAI and SES-CD, assessed by central read
  • Elevated very soft or liquid stool frequency and/or abdominal pain
  • Must have no response, insufficient response, loss of response and/or intolerance to at least 1 conventional therapy (e.g. ) or advanced therapy

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of ulcerative colitis, indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis or active diverticular disease
  • Short gut syndrome
  • Presence of an ostomy or ileoanal pouch
  • Bowel resection or diversion with \~6-months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Treatment Sequence A; Drug: Afimkibart (RO7790121) Induction dose A, Maintenance dose and OLE dose

    Drug: Afimkibart

  • Experimental
    Treatment Sequence B; Drug: Afimkibart (RO7790121) Induction dose B, Maintenance dose and OLE dose

    Drug: Afimkibart

Interventions

  • Afimkibart will be administered during the Induction, Maintenance and OLE period.

    Also known as: RO7790121, RVT-3101, PF-06480605

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (TEAE), Serious Adverse Events (SAE) and AE Leading to Discontinuation

    Time frame: Until end of study, approximately 5 years

Secondary outcomes

  1. Proportion of Participants Achieving Endoscopic Response

    Endoscopic response defined as decrease in Simple Endoscopic Score for Crohn's Disease (SES-CD) \>=50% from Baseline at Week 14

    Time frame: Week 14

  2. Proportion of Participants Achieving Clinical Remission by Crohn's Disease Activity Index (CDAI)

    Clinical remission defined as CDAI \<150 at Week 14

    Time frame: Week 14

  3. Proportion of Participants Achieving Clinical Remission by Patient Reported Outcome 2 (PRO2)

    Clinical remission by PRO2 defined as average daily very soft or liquid stool frequency (SF) \<= 2.8 and abdominal pain (AP) score \<=1, and not worse than Baseline at Week 14.

    Time frame: Week 14

  4. Trough Concentration (Ctrough)

    Time frame: Up to Week 64

07

Study locations

11 sites
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Dec 2026, 41 months after the start.

Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's planned 41 months is above that.

Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2023
First posted
Jun 18, 2023
StartActual
Jul 24, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05910528
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 18, 2023
Start date
Jul 24, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Sep 16, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Afimkibart

Start the discussion